ARTIFICIAL INTELLIGENCE-AUGMENTED CELLULAR IMAGING IN ACUTE MYELOID LEUKEMIA (DIAGNOSIS, PROGNOSIS, STRATIFICATION)
- Preclinical development
- AML
- Targeted therapy
- Immunotherapy
- Chemotherapy
- Preclinical research (TRL 4-5)
Artificial intelligence (AI) platform for integrating next-generation cell imaging data with biological data (cytogenetics, flow cytometry, molecular, genomics)
A new cell microscopy technology for diagnosis, prognosis and preclinical drug evaluation or patient population stratification.
Description
Scope of research activities
Preclinical research using new AI-augmented cell microscopy technology with biological data.
- Evaluation of drug candidates
- Stratification of patient populations
Conduct of studies
Steps:
- Evaluation of questions and objectives
- Study and experimental design
- Experimental and analytical implementation
- Valorization of results
Research infrastructure
Experimental and analytical platforms:
- Cellular microscopy integrating biological data using AI technology
Models:
- Primary patient samples
Technical personnel:
- Technicians / Engineers
Specifications
The platform
New cell microscopy technology for correlating imaging data with biological data.
The studies
Production of an optical twin using synthetic holography: 3D representation of figurative elements in blood and bone marrow.
Integration of imaging data with :
- Cytomorphological examination of bone marrow
- Blood and/or bone marrow analysis: flow cytometry, cytogenetics, molecular biology or genomics
- Deep learning
Examples of partnerships
LABCOM Optical Twin For Diagnosis OT4D - Development of new approaches to next-generation optical microscopy to feed artificial intelligence tools for diagnosis, prognostic stratification and monitoring of blood diseases.
Partners: TRIBVN ; Sorbonne Center for Artificial Intelligence ; Telecom Sud Paris ; APHP
Terms
OPALE entity
CRSA (UMR-938)
Head of Entity
Contact
Dr. Sandrine PalcyBusiness Development Director